secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2024-02-12T23:59:59+00:00
Accession:  0001104659-24-014028
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel Therapeutics amends credit to waive going concern; FDA Fast Track for BXCL701
--------------------------------------------------------------------------------

- Lenders waived 2023 going concern covenant; requires at least $40M equity raise by Feb 20, 2024.
- FDA granted Fast Track designation for BXCL701 + checkpoint inhibitor in metastatic small cell neuroendocrine prostate cancer.
- Third Amendment to Oaktree credit agreement avoids default but with capital raise condition.
- Condition subsequent: Borrower must receive $40M gross proceeds from public sale of stock/warrants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465924014028/0001104659-24-014028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465924014028/tm244487d3_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-014028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer